Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Smoking Cessation
Interventions
BIOLOGICAL

NicVAX vaccine

NicVAX vaccine given 6 times over 6 months

BIOLOGICAL

Placebo

Placebo vaccine given 6 times over 6 months

Trial Locations (25)

14263

NicVAX Investigator, Buffalo

21224

NicVAX Investigator, Baltimore

29464

NicVAX Investigator, Mt. Pleasant

32806

NicVAX Investigator, Orlando

33606

NicVAX Investigator, Tampa

33709

NicVAX Investigator, St. Petersburg

34601

NicVAX Investigator, Brooksville

37203

NicVAX Investigator, Nashville

45237

NicVAX Investigator, Cincinnati

46202

NicVAX, Indianapolis

53711

NicVAX Investigator, Madison

55414

NicVAX Investigator, Minneapolis

55905

NicVAX Investigator, Rochester

68134

NicVAX Investigator, Omaha

80204

NicVAX Investigator, Denver

83704

NicVAX Investigator, Boise

84020

NicVAX Investigator, Salt Lake City

84107

NicVAX Investigator, Salt Lake City

85724

NicVAX Investigator, Tucson

90720

NicVAX Investigator, Los Alamitos

91316

NicVAX Investigator, Encino

92108

NicVAX Investigator, San Diego

92660

NicVAX, Newport Beach

98104

NicVAX Investigator, Seattle

700006

NicVAX Investigator, Metarie

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Nabi Biopharmaceuticals

INDUSTRY

NCT01178346 - Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies | Biotech Hunter | Biotech Hunter